Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.diabet.2020.07.006 http://scihub22266oqcxt.onion/10.1016/j.diabet.2020.07.006 32750451!7395819!32750451     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32750451&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Diabetes+Metab 2020 ; 46 (6): 423-426 Nephropedia Template TP {{tp|p=32750451|t=2020. Metformin and COVID-19: From cellular mechanisms to reduced mortality |pdf=|usr=}}{{32750451}} gab.com Text Metformin and COVID-19: From cellular mechanisms to reduced mortality JO: Diabetes Metab http://www.kidney.de/pget.php?&tw=1&pmid=32750451 #FOAvip Type 2 diabetes mellitus (T2DM) is associated with both poorer clinical outcomes during the COVID-19 pandemic and an increased risk of death in such hospitalized patients. While the role of glucose control has been emphasized to improve the prognosis, the impact of different glucose-lowering agents remains largely unknown. Metformin remains the first-line pharmacological choice for the management of hyperglycaemia in T2DM. Because metformin exerts various effects beyond its glucose-lowering action, among which are anti-inflammatory effects, it may be speculated that this biguanide might positively influence the prognosis of patients with T2DM hospitalized for COVID-19. The present concise review summarizes the available data from observational retrospective studies that have shown a reduction in mortality in metformin users compared with non-users, and briefly discusses the potential underlying mechanisms that might perhaps explain this favourable impact. However, given the potential confounders inherently found in observational studies, caution is required before drawing any firm conclusions in the absence of randomized controlled trials. Twit Text FOAVip Metformin and COVID-19: From cellular mechanisms to reduced mortality ????Diabetes Metab http://www.kidney.de/pget.php?&tw=1&pmid=32750451 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32750451 #FOAvip English Wikipedia <ref>{{Cite pmid|32750451}}</ref> Metformin and COVID-19: From cellular mechanisms to reduced mortality #MMPMID32750451 Scheen AJ Diabetes Metab 2020[Nov]; 46 (6): 423-426 PMID32750451show ga Type 2 diabetes mellitus (T2DM) is associated with both poorer clinical outcomes during the COVID-19 pandemic and an increased risk of death in such hospitalized patients. While the role of glucose control has been emphasized to improve the prognosis, the impact of different glucose-lowering agents remains largely unknown. Metformin remains the first-line pharmacological choice for the management of hyperglycaemia in T2DM. Because metformin exerts various effects beyond its glucose-lowering action, among which are anti-inflammatory effects, it may be speculated that this biguanide might positively influence the prognosis of patients with T2DM hospitalized for COVID-19. The present concise review summarizes the available data from observational retrospective studies that have shown a reduction in mortality in metformin users compared with non-users, and briefly discusses the potential underlying mechanisms that might perhaps explain this favourable impact. However, given the potential confounders inherently found in observational studies, caution is required before drawing any firm conclusions in the absence of randomized controlled trials. |*SARS-CoV-2[MESH] |Aged[MESH] |COVID-19/*epidemiology/*mortality[MESH] |Comorbidity[MESH] |Diabetes Mellitus, Type 2/*drug therapy/epidemiology/mortality[MESH] |Hospitalization[MESH] |Humans[MESH] |Hypoglycemic Agents/*therapeutic use[MESH] |Inflammation/prevention & control[MESH] |Male[MESH] |Metformin/*therapeutic use[MESH] |Middle Aged[MESH]Metformin and COVID-19: From cellular mechanisms to reduced mortality (epmc).pdf DeepDyve Pubget Overpricing